HDAC6 and diffuse large B-cell lymphoma: It is that Histone deacetylation causes gene silencing and inhibits CD20 expression deficiency, is a major obstacle to retreatment of relapsed/refractory DLBCL with rituximab-related regimens, inhibition of HDAC6 activity considerably enhances CD20 levels in established B-cell tumor cell lines and primary malignant cells37.